Congestive heart failure and calcium channel blockers
Pro Research Analysisby 
Searched over 200M research papers
The Role of Calcium Channel Blockers in Congestive Heart Failure
Introduction to Congestive Heart Failure and Calcium Channel Blockers
Congestive heart failure (CHF) is a prevalent condition characterized by high morbidity and mortality. The use of calcium channel blockers (CCBs) in CHF treatment has been a subject of debate due to their mixed effects on heart function. This article synthesizes current research on the efficacy and safety of CCBs in managing CHF.
Potential Benefits and Risks of Calcium Channel Blockers
Benefits of Calcium Channel Blockers
CCBs offer several potential benefits for CHF patients. These include vasodilatory properties, anti-ischemic effects, and improvements in endothelial function and atherosclerosis development. Additionally, CCBs can positively influence calcium cycling at the molecular level, which may be beneficial for heart function1.
Risks and Negative Effects
Despite these potential benefits, CCBs also pose significant risks. They can have direct negative inotropic effects, which may worsen heart function by reducing the force of cardiac contractions. There is also a risk of neuroendocrine activation, which can further complicate CHF management1 4.
Clinical Outcomes with Different Calcium Channel Blockers
Dihydropyridine Agents
Short-acting dihydropyridine agents have not shown long-term clinical benefits in CHF patients. However, amlodipine, a third-generation dihydropyridine, has demonstrated some promise, particularly in nonischemic heart failure, with evidence suggesting a potential mortality benefit1 7.
Non-Dihydropyridine Agents
Diltiazem may be beneficial for patients with nonischemic heart failure due to its vasodilatory and negative chronotropic effects without significantly impacting inotropy. Verapamil, on the other hand, has a neutral effect on CHF but may be useful in combination with ACE inhibitors1 5.
Mibefradil
Mibefradil, a T-type calcium channel blocker, was evaluated in the MACH-1 study. The results indicated no significant benefit in CHF management, and there was a trend towards increased mortality, particularly when combined with antiarrhythmic drugs2.
Comparative Studies and Long-Term Effects
Nifedipine and Nisoldipine
Nifedipine has shown a generally beneficial hemodynamic response in CHF patients, with improvements in cardiac index and reductions in left ventricular filling pressure. However, its long-term effects remain uncertain. Nisoldipine, another dihydropyridine, has also been evaluated with some positive outcomes in severe CHF cases5 6.
Lacidipine
Lacidipine, a second-generation dihydropyridine, has shown promising results in a small study. It improved cardiac output and reduced vascular resistance without significant changes in filling pressures or heart rate, suggesting it may be a viable option for CHF patients9.
Conclusion
The role of calcium channel blockers in congestive heart failure remains complex. While certain CCBs like amlodipine and lacidipine show potential benefits, others like mibefradil have not demonstrated significant efficacy and may even pose risks. The choice of CCBs in CHF treatment should be carefully considered, taking into account the specific type of heart failure and the individual patient's condition. Further research is needed to fully understand the long-term effects and optimal use of these agents in CHF management.
Sources and full results
Most relevant research papers on this topic
Calcium channel blockers in cardiac failure.
Calcium channel blockers show potential benefits in nonischemic heart failure, but their role in diastolic dysfunction and ace-inhibition requires further study.
Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial.
Mibefradil, when used as adjunct therapy, did not affect the usual outcome of congestive heart failure, but potential interactions with antiarrhythmic drugs may have contributed to poor outcomes early in the study.
RCT
Large Human Trial
Highly CitedCalcium channel blocking agents in congestive heart failure.
Calcium channel blockers show potential in treating congestive heart failure and preventing myocardial ischemia in cardiomyopathies.
Calcium channel blockers and congestive heart failure.
Calcium channel blockers may worsen heart failure in patients with preexisting left ventricular dysfunction, potentially causing symptoms to be missed.
Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience.
Nifedipine improves cardiac index and left ventricular filling pressure in congestive heart failure patients, while verapamil may cause sudden decompensation and pulmonary edema, and diltiazem may be safer for use in patients with mild to moderate heart failure.
Calcium antagonists in heart failure.
Calcium channel blockers, particularly nifedipine, can improve systolic function in patients with congestive heart failure and myocardial ischaemia, but their use is limited due to concerns about negative inotropic effects and potential side effects.
In Vitro StudyIs there a role for calcium channel blockers in congestive heart failure?
Calcium channel blockers do not specifically reduce mortality in congestive heart failure, but they are safe for use in patients with heart failure.
Calcium channel blockers versus other classes of drugs for hypertension.
First-line CCBs show better reduction of cardiovascular events than beta-blockers, but diuretics are preferred for optimal cardiovascular event prevention.
Meta-Analysis
Very Rigorous JournalHighly CitedThe Potential Role of Calcium Antagonists in the Management of Congestive Heart Failure: Initial Experience with Lacidipine
Lacidipine shows promise in increasing cardiac output and reducing vascular resistance in congestive heart failure patients, with no significant changes in neurohumoral parameters.
RCT